Developer docs
API playgroundTry for free, no card

Search company profiles

Neurolutions

Full company profile

uuid0000saw

Namestring
Neurolutions
Legal namestring
Neurolutions, Inc.
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Neurolutions is a medical device company founded in 2007 as a spinout from Dr. Eric Leuthardt's lab at Washington University in St. Louis. Following a March 2025 merger with Kandu Health, the company operates under the Kandu, Inc. parent while maintaining the Neurolutions brand and the IpsiHand product identity. Its core offering is IpsiHand, the first FDA-cleared (De Novo, 2021) non-invasive Brain-Computer Interface system for at-home upper extremity rehabilitation in chronic stroke survivors (≥6 months post-stroke, age 18+). The system comprises three components: a wireless handpiece worn on the affected hand, a non-invasive EEG headset that captures 'intention to move' signals from the uninjured brain hemisphere, and a tablet that guides daily treatment and tracks progress. The therapy is grounded in Hebbian Theory and motor priming, with theta-gamma phase-amplitude coupling validated as a cortical biomarker of recovery. CMS classifies IpsiHand as Durable Medical Equipment under HCPCS code E0738, and the system is covered on a case-by-case basis by Medicare, the VA, and many private health plans.

Neurolutions generates revenue primarily through hardware sales of the IpsiHand system as a DME product, bundled with ongoing clinical support services including monthly OT-facilitated community meetings, in-person screening events, and a dedicated insurance navigation team. The go-to-market model is hybrid: enterprise field sales targeting clinicians and clinical sites for in-services and prescription generation, paired with direct-to-consumer channels where patients self-refer via the company website, screening events, and dedicated support. The primary end customer is the chronic stroke survivor; the secondary customer is the prescribing clinician. Headcount is 11–50 employees, with the leadership team combining neuroscience and medical device commercialization expertise (CEO Leo Petrossian; CSO Dr. Eric Leuthardt; CFO Nabeel Ahmed; CMO Dr. Tudor Jovin; CCO Andy Schultz; CBO Calvin Portley; CIO Seth Wilk; COO Javad Seyedzadeh; CMO/GM Kirsten Carroll).

The company is in early commercial scaling. IpsiHand completed limited launch in 2023, full market launch in 2024, and received a dedicated CMS reimbursement code plus DME classification in 2025. Capital structure includes a $26.55M round (March 2025), an undisclosed round from Amed Ventures (2018), a $1.15M round led by Ascension Ventures, BioGenerator, and Prolog Ventures (2015), a $100K seed from St. Louis Arch Angels (2012), a $2M NIH SBIR grant (2020), and a January 2026 strategic growth investment from K2 HealthVentures and Piper Sandler Merchant Bank. Clinical evidence includes randomized controlled trials published in Brain Communications and Brain-Computer Interfaces journals, with 100% of subjects demonstrating improvement on primary outcome measures and 66.7% exceeding MCID across all studies.

Short descriptiontext

Neurolutions is a medical device company that developed IpsiHand, the first FDA-cleared non-invasive Brain-Computer Interface for at-home upper extremity rehabilitation in chronic stroke survivors. Now operating under Kandu, Inc. following a March 2025 merger, it sells the DME-classified system through Medicare, VA, and private reimbursement channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVan Nuys, United States
HQ citystring
Van Nuys
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brain-computer interface therapy, stroke rehabilitation devices, neurorehabilitation medical devices, non-invasive BCI systems, durable medical equipment
Industry4 codes
PRIMARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHLACANAJ
Digital Rehabilitation & Physical Therapy Therapeutics
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLADAJAH
Neurologic Rehabilitation Centers (Stroke/TBI/SCI/MS/Parkinson’s)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)
SECONDARYHLAFAFAH
Neurorehabilitation Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Post-Acute Care & Rehabilitation Facilities
NAICS code2 codes
  • Offices of Physical, Occupational and Speech Therapists, and Audiologists62134
  • Home Health Care Services62161
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurorehabilitation Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1IpsiHand Hardware System Sales (DME)
TypeHardware Sales
Description

Neurolutions sells the IpsiHand Upper Extremity Rehabilitation System as a durable medical equipment (DME) product. CMS classified IpsiHand as DME, enabling Medicare coverage under HCPCS code E0738. The system is covered on a case-by-case basis by many health plans including Medicare and the VA. Revenue is generated from the sale of the hardware system (handpiece, headset, tablet), with the company's support team handling insurance navigation.

neurolutions.com
2Clinical and Support Services
TypeManaged Services
Description

Neurolutions provides ongoing clinical support including monthly community support meetings facilitated by an occupational therapist, real-time technical and clinical support, in-person screening events, and patient enrollment support. These services are bundled with the device sale to ensure proper use and positive outcomes.

neurolutions.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1IpsiHand Upper Extremity Rehabilitation System (hardware + support)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing is quote-based and not publicly disclosed. The system is covered by Medicare and VA on a case-by-case basis, with a dedicated support team assisting patients with insurance navigation. CMS has assigned HCPCS code E0738 ('Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories') for billing.

neurolutions.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1IpsiHand
Description

The IpsiHand Upper Extremity Rehabilitation System is an FDA-cleared, non-invasive brain-computer interface device for rehabilitation of upper extremity motor function in chronic stroke survivors. It comprises a handpiece, headset, and tablet components that enable thought-activated therapy at home.

neurolutions.com
Core offering1 text field

Neurolutions develops and sells the IpsiHand Upper Extremity Rehabilitation System, an FDA-cleared (De Novo) non-invasive brain-computer interface (BCI) designed for at-home rehabilitation of arm and hand motor function in chronic stroke survivors (adults at least 6 months post-stroke). The system comprises a wireless handpiece, a non-invasive EEG headset, and a tablet that together enable thought-activated therapy by translating the user's 'intention to move' signals from the uninjured brain hemisphere into mechanical hand movement, facilitating neuroplasticity and motor recovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Approximately 70% of clinical trial participants improved arm and hand movement
+5 more records
Product overview1 text field

Neurolutions offers a single core product—the IpsiHand Upper Extremity Rehabilitation System—which is an FDA-cleared brain-computer interface (BCI) designed for at-home rehabilitation of upper extremity motor function in chronic stroke survivors. The system comprises three integrated components: the IpsiHand Headset (non-invasive EEG device capturing brain signals), the IpsiHand Handpiece (wireless mechanical hand assist device), and the IpsiHand Tablet (user interface and progress tracking). The company was formed from a merger of Neurolutions and Kandu Health in March 2025, operating under Kandu Inc.

Product and service1 record
1IpsiHand Upper Extremity Rehabilitation System
CategoryNeurorehabilitation Medical Devices / Durable Medical Equipment
Description

An FDA-cleared, non-invasive brain-computer interface (BCI) system for at-home rehabilitation of arm and hand motor function in chronic stroke survivors. The system detects the user's intention to move via EEG signals from the uninjured brain hemisphere and mechanically assists hand movement via a wireless handpiece, facilitating neuroplasticity and motor recovery. It is classified by CMS as Durable Medical Equipment under HCPCS code E0738 and is covered by Medicare, VA, and many private health plans on a case-by-case basis.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Neurolutions merged with Kandu Health to form Kandu, Inc., a healthcare technology company focused on stroke rehabilitation. The merger combined Neurolutions' IpsiHand BCI technology with Kandu Health's stroke care platform and clinical services. Kirsten Carroll, founder and CEO of Kandu Health, became CMO and General Manager of Clinical Services at the combined entity. The merged company is headquartered in Van Nuys, CA.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Neurolutions was established out of Dr. Eric Leuthardt's lab at Washington University in St. Louis. The company was built on WashU discoveries, with initial funding support from Ascension Health Ventures. WashU startups including Neurolutions attracted record $1.7 billion in private-sector investment over the past year.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MindMaze develops digital neurotherapeutics and neurorehabilitation platforms for stroke and brain injury recovery. Directly comparable to Neurolutions as a neuro-rehab technology company targeting post-stroke upper extremity and cognitive recovery with software- and hardware-enabled therapy.

2Hocoma (DIH)
TypeDirect peer
Description

Hocoma (now part of DIH) is a leading neurorehabilitation device maker (Lokomat, Armeo). Directly comparable as a global provider of clinical upper-extremity and gait neurorehab equipment sold to hospitals and rehab centers.

TypeDirect peer
Description

Ekso Bionics develops wearable exoskeletons and robotic rehabilitation devices for stroke and spinal cord injury. Directly comparable as a publicly listed neurorehabilitation robotics company targeting upper and lower extremity motor recovery.

4Bionik Laboratories
TypeDirect peer
Description

Bionik Laboratories makes robotic rehabilitation devices (InMotion ARM) for upper extremity stroke recovery. Directly comparable as a neurorehab robotics company focused on post-stroke arm/hand motor retraining in clinical settings.

TypeDirect peer
Description

BrainCo develops non-invasive EEG-based BCI products for rehabilitation, education, and prosthetics. Directly comparable as a non-invasive BCI peer using EEG to drive rehabilitation outcomes.

TypeDirect peer
Description

Nexstim provides navigated transcranial magnetic stimulation (nTMS) systems used in stroke rehabilitation and neurosurgery planning. Directly comparable as a non-invasive brain stimulation company in the neurorehab space targeting chronic stroke motor recovery.

TypeDirect peer
Description

Saebo manufactures upper extremity orthoses and rehab devices (SaeboGlove, SaeboStretch) for stroke survivors. Directly comparable as a company selling at-home upper-limb stroke rehabilitation devices through clinicians and direct-to-patient channels.

TypeEmerging player
Description

Synchron is a BCI company developing a minimally invasive endovascular neural interface, primarily targeting paralysis. Comparable as a leading BCI peer aiming for FDA clearance in motor-restoration applications, though its delivery model (implanted stent) differs from IpsiHand's non-invasive EEG approach.

TypeEmerging player
Description

Blackrock Neurotech builds high-channel invasive BCI systems for research and clinical applications including motor restoration. Comparable as a BCI category peer focused on motor rehabilitation, though it currently serves research channels rather than at-home chronic stroke patients.

TypeDirect peer
Description

Tyromotion produces robotic and sensor-based upper-extremity rehabilitation devices (e.g., Armeo Power) used in clinical neurorehab. Directly comparable as a neurorehab device vendor focused on upper-limb motor recovery for stroke patients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurolutions

Neurorehabilitation Medical Devicesneurolutions.com

Neurolutions is a medical device company that developed IpsiHand, the first FDA-cleared non-invasive Brain-Computer Interface for at-home upper extremity rehabilitation in chronic stroke survivors. Now operating under Kandu, Inc. following a March 2025 merger, it sells the DME-classified system through Medicare, VA, and private reimbursement channels.

What Neurolutions does

Neurolutions is a medical device company founded in 2007 as a spinout from Dr. Eric Leuthardt's lab at Washington University in St. Louis. Following a March 2025 merger with Kandu Health, the company operates under the Kandu, Inc. parent while maintaining the Neurolutions brand and the IpsiHand product identity. Its core offering is IpsiHand, the first FDA-cleared (De Novo, 2021) non-invasive Brain-Computer Interface system for at-home upper extremity rehabilitation in chronic stroke survivors (≥6 months post-stroke, age 18+). The system comprises three components: a wireless handpiece worn on the affected hand, a non-invasive EEG headset that captures 'intention to move' signals from the uninjured brain hemisphere, and a tablet that guides daily treatment and tracks progress. The therapy is grounded in Hebbian Theory and motor priming, with theta-gamma phase-amplitude coupling validated as a cortical biomarker of recovery. CMS classifies IpsiHand as Durable Medical Equipment under HCPCS code E0738, and the system is covered on a case-by-case basis by Medicare, the VA, and many private health plans.

Neurolutions generates revenue primarily through hardware sales of the IpsiHand system as a DME product, bundled with ongoing clinical support services including monthly OT-facilitated community meetings, in-person screening events, and a dedicated insurance navigation team. The go-to-market model is hybrid: enterprise field sales targeting clinicians and clinical sites for in-services and prescription generation, paired with direct-to-consumer channels where patients self-refer via the company website, screening events, and dedicated support. The primary end customer is the chronic stroke survivor; the secondary customer is the prescribing clinician. Headcount is 11–50 employees, with the leadership team combining neuroscience and medical device commercialization expertise (CEO Leo Petrossian; CSO Dr. Eric Leuthardt; CFO Nabeel Ahmed; CMO Dr. Tudor Jovin; CCO Andy Schultz; CBO Calvin Portley; CIO Seth Wilk; COO Javad Seyedzadeh; CMO/GM Kirsten Carroll).

The company is in early commercial scaling. IpsiHand completed limited launch in 2023, full market launch in 2024, and received a dedicated CMS reimbursement code plus DME classification in 2025. Capital structure includes a $26.55M round (March 2025), an undisclosed round from Amed Ventures (2018), a $1.15M round led by Ascension Ventures, BioGenerator, and Prolog Ventures (2015), a $100K seed from St. Louis Arch Angels (2012), a $2M NIH SBIR grant (2020), and a January 2026 strategic growth investment from K2 HealthVentures and Piper Sandler Merchant Bank. Clinical evidence includes randomized controlled trials published in Brain Communications and Brain-Computer Interfaces journals, with 100% of subjects demonstrating improvement on primary outcome measures and 66.7% exceeding MCID across all studies.

Neurolutions firmographics

Firmographics
Name
Neurolutions
Legal name
Neurolutions, Inc.
Website
https://neurolutions.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Neurolutions is a medical device company that developed IpsiHand, the first FDA-cleared non-invasive Brain-Computer Interface for at-home upper extremity rehabilitation in chronic stroke survivors. Now operating under Kandu, Inc. following a March 2025 merger, it sells the DME-classified system through Medicare, VA, and private reimbursement channels.
Ownership category
akta.pro rank

Neurolutions industry classification

Industry
Product category
Neurorehabilitation Medical Devices
NAICS
Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134), Home Health Care Services (62161)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHLACANAJ
Digital Rehabilitation & Physical Therapy Therapeutics
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLADAJAH
Neurologic Rehabilitation Centers (Stroke/TBI/SCI/MS/Parkinson’s)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)
SECONDARYHLAFAFAH
Neurorehabilitation Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Post-Acute Care & Rehabilitation Facilities

Keywords

  • Brain-computer interface therapy
  • Stroke rehabilitation devices
  • Neurorehabilitation medical devices
  • Non-invasive BCI systems
  • Durable medical equipment

Where Neurolutions is headquartered

Location

Headquarters

HQ city
Van Nuys
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Neurolutions business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. IpsiHand Hardware System Sales (DME): Neurolutions sells the IpsiHand Upper Extremity Rehabilitation System as a durable medical equipment (DME) product. CMS classified IpsiHand as DME, enabling Medicare coverage under HCPCS code E0738. The system is covered on a case-by-case basis by many health plans including Medicare and the VA. Revenue is generated from the sale of the hardware system (handpiece, headset, tablet), with the company's support team handling insurance navigation.
  2. Clinical and Support Services: Neurolutions provides ongoing clinical support including monthly community support meetings facilitated by an occupational therapist, real-time technical and clinical support, in-person screening events, and patient enrollment support. These services are bundled with the device sale to ensure proper use and positive outcomes.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goIpsiHand Upper Extremity Rehabilitation System (hardware + support)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Neurolutions product offering

Product offering

Core offering

Neurolutions develops and sells the IpsiHand Upper Extremity Rehabilitation System, an FDA-cleared (De Novo) non-invasive brain-computer interface (BCI) designed for at-home rehabilitation of arm and hand motor function in chronic stroke survivors (adults at least 6 months post-stroke). The system comprises a wireless handpiece, a non-invasive EEG headset, and a tablet that together enable thought-activated therapy by translating the user's 'intention to move' signals from the uninjured brain hemisphere into mechanical hand movement, facilitating neuroplasticity and motor recovery.

Product overview

Neurolutions offers a single core product—the IpsiHand Upper Extremity Rehabilitation System—which is an FDA-cleared brain-computer interface (BCI) designed for at-home rehabilitation of upper extremity motor function in chronic stroke survivors. The system comprises three integrated components: the IpsiHand Headset (non-invasive EEG device capturing brain signals), the IpsiHand Handpiece (wireless mechanical hand assist device), and the IpsiHand Tablet (user interface and progress tracking). The company was formed from a merger of Neurolutions and Kandu Health in March 2025, operating under Kandu Inc.

Differentiator

Problem solved

Functional benefit

Brands

  • IpsiHand: The IpsiHand Upper Extremity Rehabilitation System is an FDA-cleared, non-invasive brain-computer interface device for rehabilitation of upper extremity motor function in chronic stroke survivors. It comprises a handpiece, headset, and tablet components that enable thought-activated therapy at home.

Products and services

  • IpsiHand Upper Extremity Rehabilitation System An FDA-cleared, non-invasive brain-computer interface (BCI) system for at-home rehabilitation of arm and hand motor function in chronic stroke survivors. The system detects the user's intention to move via EEG signals from the uninjured brain hemisphere and mechanically assists hand movement via a wireless handpiece, facilitating neuroplasticity and motor recovery. It is classified by CMS as Durable Medical Equipment under HCPCS code E0738 and is covered by Medicare, VA, and many private health plans on a case-by-case basis.

Quantifiable outcome

  • Approximately 70% of clinical trial participants improved arm and hand movement
  • +5 more outcomes

Companies that use Neurolutions

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Neurolutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Neurolutions partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Kandu HealthcoreStrategic or Co-development Partner · 1 December 2024Neurolutions merged with Kandu Health to form Kandu, Inc., a healthcare technology company focused on stroke rehabilitation. The merger combined Neurolutions' IpsiHand BCI technology with Kandu Health's stroke care platform and clinical services. Kirsten Carroll, founder and CEO of Kandu Health, became CMO and General Manager of Clinical Services at the combined entity. The merged company is headquartered in Van Nuys, CA.
  • Washington University in St. LouiscoreStrategic or Co-development PartnerNeurolutions was established out of Dr. Eric Leuthardt's lab at Washington University in St. Louis. The company was built on WashU discoveries, with initial funding support from Ascension Health Ventures. WashU startups including Neurolutions attracted record $1.7 billion in private-sector investment over the past year.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Neurolutions competitors and assessment

Company assessment

Direct peers

  • MindMaze: MindMaze develops digital neurotherapeutics and neurorehabilitation platforms for stroke and brain injury recovery. Directly comparable to Neurolutions as a neuro-rehab technology company targeting post-stroke upper extremity and cognitive recovery with software- and hardware-enabled therapy.
  • Hocoma (DIH): Hocoma (now part of DIH) is a leading neurorehabilitation device maker (Lokomat, Armeo). Directly comparable as a global provider of clinical upper-extremity and gait neurorehab equipment sold to hospitals and rehab centers.
  • Ekso Bionics: Ekso Bionics develops wearable exoskeletons and robotic rehabilitation devices for stroke and spinal cord injury. Directly comparable as a publicly listed neurorehabilitation robotics company targeting upper and lower extremity motor recovery.
  • Bionik Laboratories: Bionik Laboratories makes robotic rehabilitation devices (InMotion ARM) for upper extremity stroke recovery. Directly comparable as a neurorehab robotics company focused on post-stroke arm/hand motor retraining in clinical settings.
  • BrainCo: BrainCo develops non-invasive EEG-based BCI products for rehabilitation, education, and prosthetics. Directly comparable as a non-invasive BCI peer using EEG to drive rehabilitation outcomes.
  • Nexstim: Nexstim provides navigated transcranial magnetic stimulation (nTMS) systems used in stroke rehabilitation and neurosurgery planning. Directly comparable as a non-invasive brain stimulation company in the neurorehab space targeting chronic stroke motor recovery.
  • Saebo: Saebo manufactures upper extremity orthoses and rehab devices (SaeboGlove, SaeboStretch) for stroke survivors. Directly comparable as a company selling at-home upper-limb stroke rehabilitation devices through clinicians and direct-to-patient channels.
  • Tyromotion: Tyromotion produces robotic and sensor-based upper-extremity rehabilitation devices (e.g., Armeo Power) used in clinical neurorehab. Directly comparable as a neurorehab device vendor focused on upper-limb motor recovery for stroke patients.

Emerging players

  • Synchron: Synchron is a BCI company developing a minimally invasive endovascular neural interface, primarily targeting paralysis. Comparable as a leading BCI peer aiming for FDA clearance in motor-restoration applications, though its delivery model (implanted stent) differs from IpsiHand's non-invasive EEG approach.
  • Blackrock Neurotech: Blackrock Neurotech builds high-channel invasive BCI systems for research and clinical applications including motor restoration. Comparable as a BCI category peer focused on motor rehabilitation, though it currently serves research channels rather than at-home chronic stroke patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Neurolutions social profiles

Digital presence

Neurolutions compliance and trust

Trust signal

Compliance7 records

Neurolutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurolutions leadership team

Management profile

Number of profiles

Profiles19 records

Neurolutions funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurolutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurolutions

What does Neurolutions do?

Neurolutions develops and sells the IpsiHand Upper Extremity Rehabilitation System, an FDA-cleared (De Novo) non-invasive brain-computer interface (BCI) designed for at-home rehabilitation of arm and hand motor function in chronic stroke survivors (adults at least 6 months post-stroke). The system comprises a wireless handpiece, a non-invasive EEG headset, and a tablet that together enable thought-activated therapy by translating the user's 'intention to move' signals from the uninjured brain hemisphere into mechanical hand movement, facilitating neuroplasticity and motor recovery.

Is Neurolutions a public or private company?

Neurolutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neurolutions founded?

Neurolutions was founded in 2007. It employs 11 to 50 people.

Where is Neurolutions based?

Neurolutions is headquartered in Van Nuys, United States, in the North America region.

How does Neurolutions make money?

Two revenue lines are on record. IpsiHand Hardware System Sales (DME) is the primary driver. The others are clinical and Support Services.

Who are Neurolutions's main competitors?

Direct peers on record are MindMaze, Hocoma (DIH), Ekso Bionics, Bionik Laboratories, BrainCo, Nexstim, Saebo and Tyromotion. Emerging players are Synchron and Blackrock Neurotech.

Does Neurolutions have an API?

No public API is recorded for Neurolutions.

What industry is Neurolutions in?

Neurolutions's product category is Neurorehabilitation Medical Devices. Its primary akta.pro industry code is HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices), with a secondary code of HLACANAJ, Digital Rehabilitation & Physical Therapy Therapeutics. Its NAICS code is 62134 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNeurorehabilitation Devices Market to reach USD 6.98 Billion by 2035 at 14.8% CAGRThe global neurorehabilitation devices market is projected to grow from USD 2.17 billion in 2026 to USD 6.98 billion by 2035, representing a compound annual growth rate of 14.8%—nearly three times the growth rate of the broader medical device sector. This expansion is driven by three structural forces: rising global neurological disorder prevalence affecting over 1 billion people, accelerating regulatory approvals for brain-computer interface devices including the FDA's 2021 De Novo clearance of the IpsiHand System, and the emergence of AI-powered personalized rehabilitation protocols that dynamically adjust therapy based on real-time patient data. The competitive landscape is moderately fragmented, with Hocoma, Ekso Bionics, Bionik Laboratories, Medtronic, Abbott Laboratories, MindMaze, Neurolutions, BrainCo, and Nexstim among the key players collectively holding 42–48% combined revenue share.NeuroNewsBCI-enabled stroke rehabilitation therapy significantly improves functional outcomes in randomised trialKandu announced results from the first randomized controlled trial evaluating its FDA-cleared IpsiHand brain-computer interface therapy in chronic stroke survivors, showing that patients achieved a mean improvement of 6 points on the upper-extremity Fugl-Meyer scale compared to 1.5 points in the control group, with 55.5% of BCI therapy patients achieving clinically meaningful response versus 9.6% in the control arm. The trial, which enrolled 62 participants with a mean time since stroke of 5.4 years and was stopped early for efficacy, demonstrated a number needed to treat of 2.2. The IpsiHand system, originally developed by Neurolutions before its merger with Kandu last year, received FDA 510(k) clearance as a breakthrough-designated device in 2021 and is now commercially available as prescribed durable medical equipment for at-home use.MnawatchIntegrating Telehealth and BCI in Stroke Recovery — M&A WatchKandu Health and Neurolutions, Inc. merged on April 8, 2025, to form Kandu, Inc., combining telehealth stroke rehabilitation services with non-invasive brain-computer interface hardware. The transaction was accompanied by a $30 million funding round co-led by Ally Bridge Group and AMED Ventures to support commercialization and manufacturing expansion. This strategic combination aims to provide an end-to-end home-based stroke recovery solution leveraging FDA-cleared technology and established clinical pathways.AnthemDME.00052 Brain Computer Interface Rehabilitation DevicesA medical policy document classifies brain-computer interface (BCI) rehabilitation devices, specifically the IpsiHand system by Neurosolutions, Inc., as investigational and not medically necessary due to limited scientific evidence. The rationale cites studies with methodological flaws, including high dropout rates and lack of control groups, which limit the reliability of findings regarding motor function improvement in stroke survivors.openPR.comBrain-Computer Interface Market is projected to reach US$ 346.2 million by 2031 | Neurolutions, Inc., Synchron, Neuralink, BrainGate., Paradromics., Cognixion, EMOTIV, Bitbrain TechnologiesThe brain-computer interface market for paraplegia was valued at $238.5 million in 2023 and is projected to reach $346.2 million by 2031, a 4.2% CAGR. The market includes companies like Neurolutions, Neuralink, and Blackrock Neurotech, with FDA approvals for IpsiHand and MoveAgain.openPR.comBrain-Computer Interfaces for Paraplegia Market Expands to $346.2 Million by 2031 | Top Major Companies likes - Neurolutions, Inc., Synchron, Neuralink, Blackrock Neurotech., BrainGate., Paradromics.,The global brain-computer interface market for paraplegia reached $238.5 million in 2023 and is projected to reach $346.2 million by 2031, a CAGR of 4.2%. Major players include Neurolutions, Neuralink, and Blackrock Neurotech, with FDA approvals and human trials advancing clinical use.HLTHKandu Health and Neurolutions Merge to Form Stroke Recovery LeaderKandu, Inc. was formed through the merger of Kandu Health and Neurolutions to advance stroke recovery technology and services.YahooKandu Health merges with BCI company NeurolutionsKandu Health and Neurolutions merged and raised $30 million to support stroke recovery, combining Neurolutions' brain-computer interface IpsiHand with Kandu's telehealth services. The FDA-cleared device translates brain signals to move a hand brace, and the company aims to lower post-stroke quality-of-life ratings.MassDeviceKandu Health, Neurolutions merge into BCI company targeting stroke careKandu Health and Neurolutions merged to form Kandu Inc., combining BCI technology with telehealth for stroke recovery. The company raised $30 million in financing led by Ally Bridge Group and AMED Ventures. The merger aims to offer end-to-end stroke care from post-acute through chronic rehabilitation.openPR.comBrain-Computer Interfaces in Paraplegia Market Size Analysis and Regional Analysis Forecast (2024-2031) | Neurolutions, Inc., Synchron, Neuralink.The global brain-computer interfaces in paraplegia market reached US$238.5 million in 2023 and is projected to reach US$346.2 million by 2031, a CAGR of 4.2%. The market is driven by neurotechnology advancements and demand for assistive devices, with key players including Neurolutions, Synchron, and Neuralink.